Skip to main content

Klassische Methoden des Androgenentzugs in der Therapie des fortgeschrittenen Prostatakarzinoms

  • Conference paper

Zusammenfassung

Das Prostatakarzinom ist die zweit- bzw. dritthäufigste Krebstodesursache aller Männer in den westlichen Industriestaaten (Silverberg 1982). In der Bundesrepublik Deutschland ist das Prostatakarzinom mit über 8000 Todesfällen/Jahr die dritthäufigste Krebstodesursache. Für Männer, älter als 55 Jahre ist das Prostatakarzinom sogar die führende Krebstodesursache. Neben dieser hohen Mortalitätsrate weist das Prostatakarzinom auch eine hohe jährliche Inzidenzrate auf. In den Vereinigten Staaten beispielsweise macht das Prostatakarzinom 17% aller jährlich neu entdeckten Krebserkrankungen bei Männern aus (Silverberg 1982). Umgerechnet auf die derzeitige Lebenserwartung bedeutet dies, daß jeder 20. weiße Amerikaner ein klinisch manifestes Prostatakarzinom entwickeln wird (Seidmann et al. 1978). Die Inzidenzrate bei amerikanischen Farbigen liegt sogar noch höher. Statistisch wird sich bei jedem 10. zu Lebzeiten ein klinisch manifestes Prostatakarzinom entwickeln (Mettlin 1983). Weniger als 1% aller klinisch manifesten Prostatakarzinome werden vor dem 50. Lebensjahr diagnostiziert. Die Inzidenz des Prostatakrebses steigt dann aber mit zunehmendem Lebensalter rapide und schneller an als die jeder anderen Krebsform (Young et al. 1981). Aus diesen epidemiologischen Daten ergibt sich, daß mit der allgemein zunehmenden Lebenserwartung die Inzidenz des klinisch manifesten Prostatakarzinoms weiter ansteigen wird, wie sie auch in den letzten 50 Jahren ständig angestiegen ist (Devesa u. Silverman 1978). Hieraus leiten sich statistische Analysen ab, nach denen das Prostatakarzinom innerhalb der nächsten 20–25 Jahre die häufigste Krebstodesursache aller Männer sein wird.

This is a preview of subscription content, access via your institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adler A, Burger H, Davis J, Dulmanis A, Hudson B, Sarfaty G, Straffon W (1968) Carcinoma of prostate: Response of plasma luteinizing hormone and testosterone to oestrogen therapy. Br Med J 1: 28

    CrossRef  Google Scholar 

  • Baba S, Janetschek G, Pollow K, Hahn K, Jacobi GH (1982) The effects of clorotrianisene (Tace) on kinetics of 3H-testosterone metabolism in patients with carcinoma of the prostate. Br J Urol 54: 393

    PubMed  CrossRef  CAS  Google Scholar 

  • Bailar JC, Byar DP, Veterans Administration Cooperative Urological Research Group (1970)

    Google Scholar 

  • Estrogen Treatment for cancer of the prostate. Cancer 26:257

    Google Scholar 

  • Baker HW, Burger HG, de Kretser DM, Hudson B, Straffon WG (1973) Effects of synthetic oral estrogens in normal men and patients with prostatic carcinoma. Lack of gonadotrophin suppression by chlorotrianisene. Clin Endocrinol 2: 297

    CrossRef  CAS  Google Scholar 

  • Beck PH, McAnnich JW, Goebel JL, Stutzman RE (1978) Plasma testosterone in patients receiving diethylstilbestrol. Urology 11: 157

    PubMed  CrossRef  CAS  Google Scholar 

  • Blackard CE, Byar DP, Jordan WP jr, The Veterans Administration Cooperative Urological Research Group (1973) Orchiectomy for advanced prostatic carcinoma. A réévaluation. Urology 1: 553

    CAS  Google Scholar 

  • Brendler H, Prout GR jr (1962) A cooperative group study of prostatic cancer: Stilbestrol versus placebo in advanced progressive disease. Cancer Chemother Rep 16: 323

    PubMed  CAS  Google Scholar 

  • Catalona WJ, Scott WW (1986) Carcinoma of the prostate. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA (eds) Campbell’s Urology, 5th ed, WB Saunders, Philadelphia, S 1463–1534

    Google Scholar 

  • Clark P, Houghton L (1977) Subcapsular orchiectomy for carcinoma of the prostate. Br J Urol 49: 419

    PubMed  CrossRef  CAS  Google Scholar 

  • Devesa S, Silverman DT (1978) Cancer incidence and morbidity trends in the United States: 1935–1974. J Natl Cancer Inst 60: 545

    PubMed  CAS  Google Scholar 

  • Elder JS, Gibbons SRP (1985) Results of trends of the USA National Prostatic Cancer Project. Prog Clin Biol Res 185 (A): 221

    Google Scholar 

  • Ellis WJ, Isaacs JT (1985) Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dumming R-3327 system of rat prostatic adenocarcinoma. Cancer Res 45: 6041

    PubMed  CAS  Google Scholar 

  • Farnsworth W, Gonder MJ (1977) Prolactin and prostate cancer. Urology 10: 33

    PubMed  CrossRef  CAS  Google Scholar 

  • Glashan RW, Robinson MRG (1981) Cardiovascular complications in the treatment of prostatic carcinoma. Br J Urol 53: 624

    PubMed  CrossRef  CAS  Google Scholar 

  • Huggins C, Clark PJ (1940) Quantitative studies of prostatic secretion. II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostatic glands of dogs. J Exp Med 72: 747

    PubMed  CrossRef  CAS  Google Scholar 

  • Huggins C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293

    CAS  Google Scholar 

  • Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209

    CrossRef  CAS  Google Scholar 

  • Huggins C, Scott WW, Hodges CV (1941) Studies on prostatic cancer. III. The effects of fever, desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 46: 997

    CAS  Google Scholar 

  • Isaacs JT, Coffey DS (1981) Adaption vs. selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dumming R-3327-H adenocarcinoma. Cancer Res 41: 5070

    PubMed  CAS  Google Scholar 

  • Jacobi GH, Altwein JE (1978) Bromocriptin, ein neues therapeutisches Prinzip beim Prostata-Adenom und -Karzinom. Dt med Wschr 103: 827

    CrossRef  CAS  Google Scholar 

  • Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: DeVita VT, Hellman S, Rosenberg S (Hrsg) Important advances in oncology 1985. J.B. Lippincott, Philadelphia, S 193ff

    Google Scholar 

  • Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128: 335

    PubMed  CAS  Google Scholar 

  • The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311: 1281

    CrossRef  Google Scholar 

  • Lukkarinen O, Hammond GL, Kontturi M, Vikko R (1981) Long-term effects of endocrine treatment on serum pituitary hormones in advanced prostatic carcinoma patients. Scand J Urol Nephrol 15: 207

    PubMed  CrossRef  CAS  Google Scholar 

  • Mackler MA, Liberti JP, Smith MJV, Koonth WW jr, Prout GR jr (1972) The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate. Invest Urol 9: 423

    PubMed  CAS  Google Scholar 

  • Mettlin G (1983) Epidemiology of prostate cancer in different population groups. Clin Oncol 2: 287

    Google Scholar 

  • Murphy GP, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala Ch, Gaeta JF, Gibbons RP, Loening SA, McKiel ChF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264–1272

    PubMed  CrossRef  CAS  Google Scholar 

  • Nesbit RM, Plumb RT (1946) Prostatic carcinoma: A follow-up on 795 patients treated prias to endocrine era and patients treated with endocrine therapy. Surgery 20: 263

    PubMed  CAS  Google Scholar 

  • Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma. Clinical and statistical survey of 181 cases. JAMA 143: 1317

    CrossRef  CAS  Google Scholar 

  • O’Connor VJ, Chiang SP, Grayhack JT (1963) Is subcapsular orchiectomy a difinitive procedure? Studies of hormone excretion before and after orchiectomy. J Urol 89: 236

    Google Scholar 

  • Oesterling JR, Epstein JI, Walsh PC (1986) Inability of adrenal androgens to stimulate adult human prostate. Autopsy Evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol 136: 1030

    PubMed  CAS  Google Scholar 

  • Prout GR jr, Kliman B, Daly JJ, McLaughlin RA, Griffin PP, Young HH, II (1976) Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis. Urology 7: 148

    PubMed  CrossRef  CAS  Google Scholar 

  • Redding TW, Schally AV (1985) Investigation of the combination of the agonist D-Trp-6-LHRH and the antiandrogen Flutamide in the treatment of Dunning R-3327-H prostatic cancer model. Prostate 6: 219

    PubMed  CrossRef  CAS  Google Scholar 

  • Robinson MRG, Thomas BS (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 4: 391

    PubMed  CrossRef  CAS  Google Scholar 

  • Schröder FH, Kliju JG, de Jorg FA (1986) Metastatic cancer of the prostate managed by Buserelin acetate versus Buserelin acetate plus Cyproteron acetate. J Urol 135: 202A

    Google Scholar 

  • Schulze H, Isaacs JT (1986) Biology and therapy of prostatic cancer. Cancer Surv Vol 5, No 3

    Google Scholar 

  • Schulze H, Isaacs JT, Senge T (1987) Inability of complete androgen blockade to increase survival of patients with advanced prostate cancer as compared to standard hormonal therapy. J Urol (in press)

    Google Scholar 

  • Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45: 1929

    PubMed  CAS  Google Scholar 

  • Seidman H, Silverberg F, Bodden A (1978) Probabilities of eventually developing and dying of cancer (risk among persons previously undiagnosed with cancer). CA-Cancer J Clin 28: 33

    PubMed  CrossRef  CAS  Google Scholar 

  • Senge T, Hülshoff T, Tunn U, Schenk B, Neumann F (1978) Testosteronkonzentrationen im Serum nach subkapsulärer Orchiektomie. Urologe A 17: 382

    PubMed  CAS  Google Scholar 

  • Shearer RJ, Hendry WF, Sommerville IF, Ferguson JD (1973) Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668

    PubMed  CrossRef  CAS  Google Scholar 

  • Silverberg F (1982) Cancer statistics. CA (New York) 32: 15

    CAS  Google Scholar 

  • Tomic R, Bergman B, Damber J-E (1983) Testicular endocrine function after wothdrawal of oestrogen treatment in patients with carcinoma of the prostate. Br. J Urol 55: 42

    PubMed  CrossRef  CAS  Google Scholar 

  • Tunn UW, Senge Th, Neumann F (1981) Serumkonzentrationen von Testosteron und Prolaktin nach operativer und medikamentöser Kastration — Eine Langzeitstudie bei Prostatakarzinom-Patienten. Verh Dtsch Ges Urol 32. Tagung ( 1980 ), Springer, Berlin Heidelberg New York, S 419–421

    Google Scholar 

  • Vest SA, Frazier TH (1946) Survival following castration for prostatic cancer. J Urol 56: 97

    PubMed  CAS  Google Scholar 

  • Veterans Administration Cooperative Urological Research Group (VACURG) (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011

    Google Scholar 

  • Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2: 125

    PubMed  CAS  Google Scholar 

  • Walsh PC, Siiteri PK (1975) Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J Urol 114: 254

    PubMed  CAS  Google Scholar 

  • Young JL, Percey CL, Asire A J (1981) Surveillance, epidemiology and end results: incidence and mortality data, 1973–1977. Natl Cancer Inst Monogr 57, DHHS Publication No (NIH) 81, Washington, DC

    Google Scholar 

  • Young HH, II, Kent JR (1968) Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol 99: 788

    PubMed  CAS  Google Scholar 

  • Zadra J, Bruce AW, Trachtenberg J (1986) Total androgen ablation therapy in the treatment of advanced prostatic cancer. J Urol 135:201 A

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Schulze, H., Senge, T. (1987). Klassische Methoden des Androgenentzugs in der Therapie des fortgeschrittenen Prostatakarzinoms. In: Nagel, R. (eds) Konservative Therapie des Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72613-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72613-2_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-17724-1

  • Online ISBN: 978-3-642-72613-2

  • eBook Packages: Springer Book Archive